凯普生物
(300639)
| 流通市值：36.65亿 | | | 总市值：37.30亿 |
| 流通股本：6.35亿 | | | 总股本：6.47亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 610,244,080.75 | 408,884,662.9 | 183,101,224.63 | 1,104,453,848.02 |
| 营业收入 | 610,244,080.75 | 408,884,662.9 | 183,101,224.63 | 1,104,453,848.02 |
| 二、营业总成本 | 678,692,168.29 | 476,911,703.15 | 228,636,430.54 | 1,098,029,672.79 |
| 营业成本 | 281,847,046.05 | 189,550,467.24 | 90,990,841.5 | 430,417,261.88 |
| 税金及附加 | 7,599,656.04 | 3,851,340.46 | 1,798,865.86 | 10,325,243.55 |
| 销售费用 | 170,995,014.41 | 115,502,447.62 | 53,777,285.75 | 279,122,721.6 |
| 管理费用 | 167,456,535.91 | 119,036,614.36 | 55,107,550.71 | 253,356,020.06 |
| 研发费用 | 64,903,343.27 | 45,839,216.09 | 24,295,791.99 | 136,321,683.55 |
| 财务费用 | -14,109,427.39 | 3,131,617.38 | 2,666,094.73 | -11,513,257.85 |
| 其中:利息费用 | 1,368,240.45 | 882,726.31 | 463,532.59 | 4,944,844.45 |
| 其中:利息收入 | 17,946,316.7 | 9,047,974.07 | 2,583,623.41 | 33,502,146.17 |
| 加:公允价值变动收益 | -513.72 | 7,448.94 | -36,871.74 | -1,834.96 |
| 加:投资收益 | 8,809,664.9 | 7,297,305.09 | 1,389,961.88 | 13,944,049.55 |
| 资产处置收益 | 1,683,652.36 | 791,920.84 | 317,275.21 | 7,060,528.61 |
| 资产减值损失(新) | -21,008,057.79 | -802,260.66 | 81,166.72 | -9,981,979.44 |
| 信用减值损失(新) | -382,091,593.16 | -73,889,560.96 | 9,930,160.83 | 10,281,542.3 |
| 其他收益 | 4,228,268.28 | 3,223,304.47 | 2,273,680.38 | 14,873,242.59 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -456,826,666.67 | -131,398,882.53 | -31,579,832.63 | 42,599,723.88 |
| 加:营业外收入 | 1,021,151.67 | 831,181.64 | 674,049.5 | 587,648.52 |
| 减:营业外支出 | 4,655,808.36 | 2,333,622.5 | 2,589,837.22 | 6,371,284.45 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -460,461,323.36 | -132,901,323.39 | -33,495,620.35 | 36,816,087.95 |
| 减:所得税费用 | -59,742,116.52 | -3,549,667.76 | -5,701,043.52 | -31,698,359.18 |
| 六、净利润 | -400,719,206.84 | -129,351,655.63 | -27,794,576.83 | 68,514,447.13 |
| 持续经营净利润 | -400,719,206.84 | -129,351,655.63 | -27,794,576.83 | 68,514,447.13 |
| 归属于母公司股东的净利润 | -261,923,132.65 | -76,929,246.55 | -14,354,781.93 | 140,472,219.75 |
| 少数股东损益 | -138,796,074.19 | -52,422,409.08 | -13,439,794.9 | -71,957,772.62 |
| (一)基本每股收益 | -0.41 | -0.12 | -0.02 | 0.25 |
| (二)稀释每股收益 | -0.41 | -0.12 | -0.02 | 0.25 |
| 八、其他综合收益 | -6,565,547.68 | 9,718,312.43 | 838,659.45 | 17,418,432.85 |
| 归属于母公司股东的其他综合收益 | -6,565,547.68 | 9,718,312.43 | 838,659.45 | 17,418,432.85 |
| 九、综合收益总额 | -407,284,754.52 | -119,633,343.2 | -26,955,917.38 | 85,932,879.98 |
| 归属于母公司股东的综合收益总额 | -268,488,680.33 | -67,210,934.12 | -13,516,122.48 | 157,890,652.6 |
| 归属于少数股东的综合收益总额 | -138,796,074.19 | -52,422,409.08 | -13,439,794.9 | -71,957,772.62 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-27 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |